Clinical trial
A Phase 2, Multicenter, Randomized, Double-blinded, and Placebo-controlled Study of the Antiviral Activity, Safety and Pharmacokinetics of VCH-759 in Subjects With Chronic Hepatitis C-infection.
NCT00389298 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, Randomized, Double-blinded, and Placebo-controlled Study of the Antiviral Activity, Safety and Pharmacokinetics of VCH-759 in Subjects With Chronic Hepatitis C-infection.
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- October 31, 2006
- Completion date
- June 30, 2007
- Enrollment
- 36 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.